Trials / Completed
CompletedNCT03133130
Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Hugel · Industry
- Sex
- Male
- Age
- 19 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
Detailed description
A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMT101 | BMT101 is administered to 6 subjects in each of 4 groups. |
| DRUG | Placebo | Placebo is administered to 2 subjects in each of 4 groups. |
Timeline
- Start date
- 2017-07-31
- Primary completion
- 2018-02-14
- Completion
- 2018-02-14
- First posted
- 2017-04-28
- Last updated
- 2018-04-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03133130. Inclusion in this directory is not an endorsement.